AdvisorShares Investments LLC Purchases 32,030 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

AdvisorShares Investments LLC lifted its position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 47.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 99,810 shares of the company’s stock after buying an additional 32,030 shares during the period. AdvisorShares Investments LLC’s holdings in Vistagen Therapeutics were worth $294,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in VTGN. JPMorgan Chase & Co. increased its position in Vistagen Therapeutics by 4,826,425.0% during the 4th quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company’s stock valued at $2,278,000 after purchasing an additional 772,228 shares during the period. Nantahala Capital Management LLC increased its holdings in Vistagen Therapeutics by 30.6% during the fourth quarter. Nantahala Capital Management LLC now owns 1,981,980 shares of the company’s stock valued at $5,847,000 after buying an additional 464,284 shares during the period. Landscape Capital Management L.L.C. bought a new position in Vistagen Therapeutics in the fourth quarter worth approximately $123,000. Prosperity Wealth Management Inc. purchased a new stake in Vistagen Therapeutics during the fourth quarter worth $86,000. Finally, Boothbay Fund Management LLC bought a new stake in Vistagen Therapeutics during the 4th quarter valued at $66,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

Vistagen Therapeutics Stock Performance

VTGN opened at $2.29 on Wednesday. The firm has a market cap of $66.09 million, a price-to-earnings ratio of -1.55 and a beta of 0.56. Vistagen Therapeutics, Inc. has a 12 month low of $1.90 and a 12 month high of $4.96. The stock has a fifty day moving average price of $2.46 and a 200-day moving average price of $2.71.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, February 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. The business had revenue of $230 billion during the quarter, compared to the consensus estimate of $0.18 million. On average, equities research analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current year.

Vistagen Therapeutics Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.